The stock of Genprex Inc (NASDAQ: GNPX) has increased by 17.16 when compared to last closing price of 0.23.Despite this, the company has seen a gain of 6.80% in its stock price over the last five trading days. prnewswire.com reported 2025-06-24 that Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical research from studies of GPX-002, the Company’s diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago. “We are proud of the research presented at the ADA conference, which demonstrates that alpha cells in animal models of T1D have undergone transdifferentiation to beta-like cells after being transduced with GPX-002.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
Moreover, the 36-month beta value for GNPX is -0.48. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GNPX is 28.22M and currently, short sellers hold a 8.14% of that float. On July 02, 2025, GNPX’s average trading volume was 4.43M shares.
GNPX’s Market Performance
GNPX’s stock has seen a 6.80% increase for the week, with a -20.01% drop in the past month and a 8.85% gain in the past quarter. The volatility ratio for the week is 11.01%, and the volatility levels for the past 30 days are at 12.69% for Genprex Inc. The simple moving average for the past 20 days is -2.87% for GNPX’s stock, with a -58.59% simple moving average for the past 200 days.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at -3.21% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.27% of loss for the given period.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -1530.6 for the present operating margin
- -0.23 for the gross margin
The net margin for Genprex Inc stands at -1926.88. The total capital return value is set at -3.92. Equity return is now at value -302.69, with -205.73 for asset returns.
Currently, EBITDA for the company is -21.1 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 431.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.94.
Conclusion
To wrap up, the performance of Genprex Inc (GNPX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
